Kevzara 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3  
amended 
on 
N/0039 
Minor change in labelling or package leaflet not 
28/06/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0038/G 
This was an application for a group of variations. 
24/05/2023 
n/a 
B.II.e.z - Change in container closure system of the 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Finished Product - Other variation 
B.II.b.1.z - Replacement or addition of a 
manufacturing site for the FP - Other variation 
B.II.e.3.b - Change in test procedure for the 
immediate packaging of the finished product - Other 
changes to a test procedure (including replacement 
or addition) 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
IB/0035 
C.I.11.z - Introduction of, or change(s) to, the 
15/02/2023 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
T/0034 
Transfer of Marketing Authorisation 
31/10/2022 
18/11/2022 
SmPC, 
Labelling and 
PL 
IB/0033 
B.II.b.1.z - Replacement or addition of a 
24/05/2022 
n/a 
manufacturing site for the FP - Other variation 
R/0029 
Renewal of the marketing authorisation. 
24/02/2022 
25/04/2022 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Kevzara in the approved indication remains favourable and 
therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
IB/0032 
B.II.d.2.d - Change in test procedure for the finished 
06/01/2022 
n/a 
product - Other changes to a test procedure 
(including replacement or addition) 
Page 2/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0030/G 
This was an application for a group of variations. 
08/12/2021 
n/a 
B.II.b.1.z - Replacement or addition of a 
manufacturing site for the FP - Other variation 
B.II.b.1.z - Replacement or addition of a 
manufacturing site for the FP - Other variation 
B.II.b.1.z - Replacement or addition of a 
manufacturing site for the FP - Other variation 
B.II.b.1.z - Replacement or addition of a 
manufacturing site for the FP - Other variation 
B.II.b.1.z - Replacement or addition of a 
manufacturing site for the FP - Other variation 
B.II.b.1.z - Replacement or addition of a 
manufacturing site for the FP - Other variation 
N/0031 
Minor change in labelling or package leaflet not 
26/11/2021 
25/04/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
II/0028/G 
This was an application for a group of variations. 
14/10/2021 
25/04/2022 
Annex II 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.a.1.j - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS -  
Replacement or addition of a site where batch 
control/testing takes place and any of the test 
method at the site is a biol/immunol method 
B.I.c.3.b - Change in test procedure for the 
immediate packaging of the AS - Other changes to a 
Page 3/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
test procedure (including replacement or addition) 
B.I.a.1.e - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
change relates to a biological AS or a starting 
material [-] used in the manufacture of a 
biological/immunological product 
B.I.a.1.j - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS -  
Replacement or addition of a site where batch 
control/testing takes place and any of the test 
method at the site is a biol/immunol method 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.a.1.k - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - New 
storage site of MCB and/or WCB 
B.I.a.1.j - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS -  
Replacement or addition of a site where batch 
control/testing takes place and any of the test 
method at the site is a biol/immunol method 
B.I.a.4.d - Change to in-process tests or limits 
applied during the manufacture of the AS - Widening 
of the approved in-process test limits, which may 
have a significant effect on the overall quality of the 
AS 
PSUSA/10609
Periodic Safety Update EU Single assessment - 
16/09/2021 
15/11/2021 
SmPC and PL 
Please refer to Kevzara 
/202101 
sarilumab 
EMEA/H/C/PSUSA/00010609/202101 EPAR: Scientific 
conclusions and grounds recommending the variation to the 
Page 4/12 
 
 
 
 
 
 
 
II/0024/G 
This was an application for a group of variations. 
21/01/2021 
n/a 
terms of the marketing authorisation 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
B.I.b.1.e - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a 
specification parameter which may have a significant 
effect on the overall quality of the AS and/or the FP 
N/0025 
Minor change in labelling or package leaflet not 
19/01/2021 
15/11/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
IAIN/0026 
B.II.b.1.a - Replacement or addition of a 
12/01/2021 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
PSUSA/10609
Periodic Safety Update EU Single assessment - 
17/09/2020 
19/11/2020 
SmPC and PL 
Please refer to EMEA/H/C/PSUSA/00010609/202001 EPAR: 
/202001 
sarilumab 
Scientific conclusions and grounds recommending the 
variation to the terms of the marketing authorisation 
II/0022/G 
This was an application for a group of variations. 
07/05/2020 
n/a 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.4.e - Change to in-process tests or limits 
applied during the manufacture of the AS - Deletion 
of an in-process test which may have a significant 
effect on the overall quality of the AS 
Page 5/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.b.2.z - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
variation 
IB/0023 
B.II.b.4.f - Change in the batch size (including batch 
30/03/2020 
n/a 
size ranges) of the finished product - The scale for a 
biological/immunological medicinal product is 
increased/decreased without process change (e.g. 
duplication of line) 
PSUSA/10609
Periodic Safety Update EU Single assessment - 
27/02/2020 
28/04/2020 
SmPC and PL 
Please refer to Kevzara 
/201907 
sarilumab 
EMEA/H/C/PSUSA/00010609/201907 EPAR: 
Scientific conclusions and grounds recommending the 
variation to the terms of the marketing authorisation 
IB/0020 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
17/02/2020 
28/04/2020 
SmPC 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
Page 6/12 
 
 
 
 
 
 
 
 
 
 
 
IB/0019/G 
This was an application for a group of variations. 
13/12/2019 
n/a 
B.II.e.6.b - Change in any part of the (primary) 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
the product information 
B.IV.1.z - Change of a measuring or administration 
device - Other variation 
IA/0018/G 
This was an application for a group of variations. 
27/11/2019 
n/a 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.b - Change in test procedure for the finished 
product - Deletion of a test procedure if an 
alternative method is already authorised 
IB/0017/G 
This was an application for a group of variations. 
17/11/2019 
28/04/2020 
Annex II and 
PL 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.c.2 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Including batch control/testing 
II/0015/G 
This was an application for a group of variations. 
17/10/2019 
n/a 
B.I.a.1.k - Change in the manufacturer of AS or of a 
Page 7/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
starting material/reagent/intermediate for AS - New 
storage site of MCB and/or WCB 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
PSUSA/10609
Periodic Safety Update EU Single assessment - 
11/07/2019 
n/a 
PRAC Recommendation - maintenance 
/201901 
sarilumab 
IB/0014 
B.II.b.5.z - Change to in-process tests or limits 
03/07/2019 
n/a 
applied during the manufacture of the finished 
product - Other variation 
N/0012 
Minor change in labelling or package leaflet not 
09/04/2019 
28/04/2020 
PL 
connected with the SPC (Art. 61.3 Notification) 
PSUSA/10609
Periodic Safety Update EU Single assessment - 
14/02/2019 
n/a 
PRAC Recommendation - maintenance 
Page 8/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
/201807 
sarilumab 
II/0011/G 
This was an application for a group of variations. 
24/01/2019 
n/a 
B.I.a.1.j - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS -  
Replacement or addition of a site where batch 
control/testing takes place and any of the test 
method at the site is a biol/immunol method 
B.I.a.2.c - Changes in the manufacturing process of 
the AS - The change refers to a [-] substance in the 
manufacture of a biological/immunological substance 
which may have a significant impact on the medicinal 
product and is not related to a protocol 
B.I.a.4.d - Change to in-process tests or limits 
applied during the manufacture of the AS - Widening 
of the approved in-process test limits, which may 
have a significant effect on the overall quality of the 
AS 
B.I.b.1.f - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Change outside the 
approved specifications limits range for the AS 
II/0010/G 
This was an application for a group of variations. 
13/12/2018 
n/a 
B.II.b.1.c - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch 
release/control, and secondary packaging, for 
biol/immunol medicinal products or pharmaceutical 
Page 9/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
forms manufactured by complex manufacturing 
processes 
B.II.b.2.b - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place for a biol/immunol 
product and any of the test methods at the site is a 
biol/immunol method 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
IA/0009 
B.II.e.6.b - Change in any part of the (primary) 
18/10/2018 
n/a 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
the product information 
IB/0007 
B.I.a.4.z - Change to in-process tests or limits 
10/08/2018 
n/a 
applied during the manufacture of the AS - Other 
variation 
PSUSA/10609
Periodic Safety Update EU Single assessment - 
12/07/2018 
n/a 
PRAC Recommendation - maintenance 
/201712 
sarilumab 
II/0006/G 
This was an application for a group of variations. 
21/06/2018 
n/a 
Page 10/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.b.5.b - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Addition of a new test(s) and limits 
B.II.d.1.e - Change in the specification parameters 
and/or limits of the finished product - Change 
outside the approved specifications limits range 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
II/0004 
B.II.d.1.e - Change in the specification parameters 
07/12/2017 
n/a 
and/or limits of the finished product - Change 
outside the approved specifications limits range 
II/0003/G 
This was an application for a group of variations. 
23/11/2017 
n/a 
B.I.a.3.c - Change in batch size (including batch size 
ranges) of AS or intermediate - The change requires 
assessment of the comparability of a 
biological/immunological AS 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
IB/0002/G 
This was an application for a group of variations. 
24/08/2017 
12/12/2018 
SmPC, 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
Labelling and 
PL 
Page 11/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
IB/0001/G 
This was an application for a group of variations. 
20/07/2017 
n/a 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.II.g.5.c - Implementation of changes foreseen in 
an approved change management protocol - For a 
biological/immunological medicinal product 
Page 12/12 
 
 
 
 
 
 
 
 
 
 
 
